25 Jan 2018 11:45
25 January 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Result of GM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol and diabetes, announces that at the General Meeting held earlier today, all resolutions were duly passed.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Stephen O'Hara, Chief Executive | Contact via Walbrook below | |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner | ||
finnCap (Broker) |
Tel: 020 7220 0500 | |
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) | ||
Tony Quirke (Corporate Broking) | ||
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com | |
Anna Dunphy | Mob: 07876 741 001 | |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health (OPTI)